Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

US10704108B2 · kind B2 · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• Duke University · US

Inventors

• Bert Vogelstein · Baltimore, US
• Kenneth W. Kinzler · Baltimore, US
• D. Williams Parsons · Bellaire, US
• Xiaosong Zhang · Baltimore, US
• Jimmy Cheng-Ho Lin · Baltimore, US
• Rebecca J. Leary · Cambridge, US
• Philipp Angenendt · Baltimore, US
• Nickolas Papadopoulos · Towson, US
• Victor Velculescu · Dayton, US
• Giovanni Parmigiani · Boston, US
• Rachel Karchin · Towson, US
• Sian Jones · Baltimore, US
• Hai Yan · Chapel Hill, US
• Darell Bigner · Mebane, US
• Chien-Tsun Kuan · Cary, US
• Gregory J. Riggins · Baltimore, US

Key dates

• Filing date: Sep 17, 2018
• Grant date: Jul 7, 2020
• Expiry date: Sep 17, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G16B40/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.